Compare · GILD vs TWST
GILD vs TWST
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $160.36B, about 37.2x TWST ($4.31B).
- Over the past year, GILD is up 14.2% and TWST is up 107.1% - TWST leads by 92.9 points.
- GILD has been more active in the news (19 items in the past 4 weeks vs 14 for TWST).
- GILD has more recent analyst coverage (25 ratings vs 13 for TWST).
- Company
- Gilead Sciences Inc.
- Twist Bioscience Corporation
- Price
- $129.00-0.17%
- $69.11-6.53%
- Market cap
- $160.36B
- $4.31B
- 1M return
- -5.32%
- +16.08%
- 1Y return
- +14.18%
- +107.09%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2018
- News (4w)
- 19
- 14
- Recent ratings
- 25
- 13
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest GILD
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Latest TWST
- Chief Financial Officer Laponis Adam sold $280,000 worth of shares (4,000 units at $70.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 112,675 units (SEC Form 4)
- Officer Cho Dennis sold $990,799 worth of shares (14,205 units at $69.75) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 120,094 units (SEC Form 4)
- Director Starovasnik Melissa A. sold $170,000 worth of shares (2,500 units at $68.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 22,222 units (SEC Form 4)
- Chief Executive Officer Leproust Emily M. exercised 16,470 shares at a strike of $8.82 and sold $1,118,555 worth of shares (16,470 units at $67.91) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Accounting Officer Werner Robert F. sold $49,987 worth of shares (800 units at $62.48), decreasing direct ownership by 2% to 48,186 units (SEC Form 4) (tax liability)
- Chief Executive Officer Leproust Emily M. exercised 49,299 shares at a strike of $8.82 and sold $3,213,653 worth of shares (49,299 units at $65.19) as part of a pre-agreed trading plan (SEC Form 4)
- Director Starovasnik Melissa A. sold $30,520 worth of shares (500 units at $61.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,722 units (SEC Form 4)
- Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
- SVP of Human Resources Green Paula sold $74,507 worth of shares (1,399 units at $53.26), decreasing direct ownership by 1% to 121,589 units (SEC Form 4) (for tax liability)
- President and COO Finn Patrick John sold $221,549 worth of shares (4,160 units at $53.26), decreasing direct ownership by 1% to 274,804 units (SEC Form 4) (withholding obligation)